CYBN:CC News and Press, CYBIN INC. From 06/29/22

New Jersey’s senate president recently filed a bill that would legalize the home cultivation, possession and gifting of psilocybin or magic mushrooms to adults aged 21 and older. The psychedelic reform bill contains provisions that would grant the psychedelics market more freedoms t...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievem...

We know that pregnancy, giving birth and navigating the first few months as a mother can have an immense toll on women’s mental health . In recent times, there has been an increased push to provide resources for new mothers to help address mental health issues such as postpartum dep...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biotechnology company focused on progressing psychedelic therapeutics, has received approval from the U.S. Food and Drug Administration (“FDA”) to proceed with its phase 1/2a first-in-human clinical trial evaluating CYB003; the ...

-- Marks the first novel psilocybin analog to enter clinical development -- -- Patient recruitment to commence immediately -- -- Pharmacokinetic and safety data readout expected in Q4 2022 -- Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the...

Over the last decade or so, a growing body of research has revealed a link between mental health and psychedelics. Researchers have found that psychedelic drugs such as LSD and psilocybin have the potential to alleviate mental health conditions , including depression and post-traumatic st...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today reported recent business highlights and audited financial results for its fiscal year ended March 31, 2022. In addition, the company reiterate...

- Company reiterates key pipeline and strategic milestones for 2022 – Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Th...

Precision medicine is a relatively new field in medical technology that has allowed doctors to peer even deeper into the human body, thus broadening the horizons of medical treatments significantly. This groundbreaking technology is now being paired with psychedelics to boost psychedelic r...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health ...